Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Radar™  A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast Cancer

Inivata, a leader in liquid biopsy, announces new data in support of its RaDaR assay for the detection of minimal residual disease (MRD) and recurrence in patients with high-risk hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Read More

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Marla Lipsyc-Sharf, MD Elza C. de Bruin, PhD Katheryn Santos, BS  Robert McEwen, PhD Daniel Stetson, MS  Ashka Patel, BS  Gregory J. ... Read More

WCLC 2022

WCLC 2022

Event expiration date display - 6 - 9 AUG 2022

Location: Vienna, Austria Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

The @myESMO Annual Meeting takes place next month. Members of #TeamInivata will be on the ground in Paris. For meetings, please contact Vishal Sikri, David Eberhard, Mike Nahorski, Huw Ricketts and Chris Pipinikas. https://www.esmo.org/meetings/esmo-congress-2022 #ESMO22

Great to see in @ICR_London, alongside many other key stakeholders, supporting the use of biomarker testing to improve cancer patient diagnosis & care. Read more in this article from @thetimes:
https://bit.ly/3p3fbuk
#diagnostics #oncology #liquidbiopsy

At Inivata, our purpose is to help guide more informed #treatments for cancer patients. To hear the story of the first #patient tested with our InVisionFirst-Lung #liquidbiopsy test for #NSCLC, please see below.

https://vimeo.com/699410987

LinkedIn tracking code Twitter tracking code